The North American Vasovagal Pacemaker Study is an ongoing multicenter
randomized, clinical trial that assesses She efficacy of dual chamber
pacing utilizing rate drop sensing in patients with frequent syncopal
spells. Patients are eligible if they have had at least six syncopal
spells and a positive tilt table test, or a recurrence of syncope with
in 6 months of a positive tilt test. The tilt table test must have pro
voked a relative bradycardia. Patients are randomized to receive a Med
tronic Thera DR with rate drop sensing, or to continue on their usual
therapy. All patients complete a log of their presyncopal and syncopal
spells daily, and are contacted every 2 months. The primary outcome m
easure is the time to the first recurrence of syncope. The goal of the
main study is to recruit 284 patients in 3 years with a final fourth
year of follow-up: this will result in an 80% chance of detecting a 30
% reduction in the risk of syncope. A pilot study is under way with th
e aim to recruit 60 patients over a period of 2 years with a final thi
rd year of follow-up, Recruitment began in July 1995 and 47 patients h
ave been enrolled to date.